|
|
 |
|
Viewing report
|
|
|
|
The Top 10 Generics Companies: Strategic Insight, Growth Opportunities and Competitive Dynamics in the US and Europe
Business Insights, March 2006, Pages: 178
The generics sector has grown at a fast pace over the past few years, outperforming the pharmaceutical market as a whole; generic growth opportunities are significant, with an estimated $100bn worth of branded pharmaceutical products to go off patent by 2010, of which $21bn expire in 2006. Although US and major European generic drug sales increased rapidly from 2000 to 2003, there has been a slowdown in growth during 2004. In response to an increasingly competitive unbranded generic pharmaceutical marketplace, and a slowdown in growth in 2004, some of the major generics players have consolidated. The two largest M&A deals in the generics market in recent years have been the acquisition of Eon and HEXAL Labs by Sandoz in February 2005, and the acquisition of IVAX by Teva in January 2006.
“The Top 10 Generics Companies: Strategic Insight, Growth Opportunities and Competitive Dynamics in the US and Europe” identifies the successful strategies utilized by the industry’s key players in the US and Western European market. The report provides insights into the top 10 generic companies strengths, weaknesses, opportunities and threats in the generic pharmaceutical market, allowing you to tailor the best practice strategies of the generic industry’s leading players to your company’s needs.
Customers who bought this item also bought
Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues
Pharmaceuticals - Global Outlook
Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
GenericHandbook - A Guide to the Generic Drug Industry in the US - 3rd Edition
Generics Threats and Opportunities: Mounting an Effective Defense Strategy
State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma
Prescription Drugs - Global Strategic Business Report
Biopharma Quarter: Key Trends and Events of the First Quarter of 2009
The Future of the Generics Industry: Opportunities, Threats and Key Trends
Antidepressants - Global Strategic Business Report
|
|
|
|
